Diabetes devices linked to surge in adverse incident reports across Australia

A surge in adverse incident reports across Australia has cast a spotlight on the safety and reliability of modern diabetes management technology. As automated insulin pumps and continuous glucose monitors (CGMs) become standard care for thousands of Australians, patients and medical experts are voicing increasing concern over device inaccuracies, alarm failures, and the consequences of integrating these life-critical tools with consumer electronics.

The Therapeutic Goods Administration (TGA) tracks safety reports in a public database, though it does not release the data in aggregate form. An investigation using automated data extraction revealed that diabetes management devices account for seven of the 10 products with the highest volume of adverse-event reports submitted since 2024. These devices also occupy five of the top 10 positions for reports involving injury or death over the same period.

Technology vs. Regulatory Oversight

The rapid adoption of this technology, which allows patients to track blood glucose levels via smartphones, has introduced unforeseen vulnerabilities. Among the most pressing concerns is the interaction between medical hardware and smartphone software. In some instances, Bluetooth connections to external devices, such as car stereos, have been linked to muted alerts, preventing users from hearing life-saving low-blood-sugar alarms.

While regulators in the United States have issued public warnings regarding the risks of Bluetooth interference, the Australian TGA has not formally passed this information on to domestic users. The regulator maintains that it publishes safety information based on internal analysis of safety signals and trends.

This issue is currently at the center of a major Victorian coronial inquest into a fatal 2023 car crash. A driver, who used an Abbott FreeStyle Libre 2 monitor, reported to the court that he did not hear low-glucose alerts in the lead-up to the accident. Experts noted that while the devices are life-changing, they are susceptible to hardware and connectivity failures that can leave patients without vital information.

Inaccuracy and Clinical Risks

Beyond connectivity, the accuracy of the sensors themselves remains a flashpoint. Many users report significant discrepancies between CGM readings and traditional finger-prick blood glucose tests. When these devices are connected to automatic insulin pumps, such as the Insulet Omnipod 5, inaccuracies can lead the system to administer incorrect insulin dosages, risking severe hyperglycaemia or hypoglycaemia.

The Omnipod 5, which is partially subsidised by the federal government, has been linked to hundreds of adverse-event reports, including cases of diabetic ketoacidosis. Meanwhile, the Dexcom G7 monitor has faced criticism following a US regulatory warning that it relied on unapproved, less-accurate sensor components. While manufacturers emphasize that the benefits of continuous monitoring outweigh the risks and that clinical evidence supports their efficacy, some practitioners remain wary.

Associate Professor Neale Cohen of the Baker Heart and Diabetes Institute has cautioned that regulatory approval for new devices does not guarantee high levels of accuracy. This sentiment is echoed by a coalition of experts who have proposed higher minimum standards for CGM devices, arguing that current benchmarks may be insufficient to protect patients from the risks of automated dosing errors.

Current Status of Major Devices

• Omnipod 5 (Insulet): Associated with hundreds of injury reports; recent batches recalled due to potential insulin leakage.
• Dexcom G6/G7: Users have reported significant data discrepancies; multiple product corrections issued for app connectivity and alarm failures.
• FreeStyle Libre (Abbott): Linked to reports of silent alarm failures, particularly when integrated with smartphone operating systems.

What to Watch Next

The regulatory and clinical environment is expected to shift as the following developments unfold:

• Coronial Outcomes: The ongoing Victorian investigation is expected to determine whether technological limitations contributed to the 2023 Daylesford crash, which may prompt changes to how device safety is communicated.
• Standardisation: Continued pressure from medical associations to implement stricter, evidence-based minimum standards for CGM sensors could force manufacturers to revise testing protocols.
• Software Compatibility: As manufacturers urge users to delay smartphone operating system updates to ensure app stability, patients face a growing tension between digital security and the reliability of their medical monitoring equipment.

For now, experts advise patients to treat device data as a support tool rather than an infallible source. When in doubt, a manual finger-prick remains the industry-standard method for verifying glucose levels—a step that some users say is essential when their digital monitors fail to reflect their physical symptoms.